SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced several scientific presentations at the International Society on Thrombosis and Haemostasis (ISTH) XII Congress in Boston that will feature its investigational antiplatelet drug elinogrel, a P2Y(12) ADP receptor antagonist currently in Phase II clinical development, and its oral Factor Xa inhibitor anticoagulant antidote in pre-clinical development, as well as a presentation by Portola co-founder David Phillips on new directions in antithrombotic drug discovery.
In the past six months, Portola has announced global development and commercialization agreements with Novartis for elinogrel and with Merck & Co., Inc. for betrixaban, an investigational oral Factor Xa inhibitor anticoagulant currently in Phase II clinical development.
A Functional Pool of P2Y12 Receptors Exposed Upon Platelet Activation Persists in Mice Treated with High Dose Clopidogrel, and Can Be Blocked by Elinogrel, a Direct Acting Reversible P2Y12 Inhibitor (Presentation #PP-MO-045)
Presenter: Helena Haberstock-Debic Date: Monday, July 13, 12:30-2:15 p.m. Location: Poster Area, Platelet Biology
New Directions in Antithrombotic Drug Discovery: Pharmacological Uncoupling of Arterial thrombosis from Hemostasis (Presentation #AS-TU-026)
Presenter: David Phillips Date: Tuesday, July 14, 1:15-1:45 p.m. Location: Room 104 ABC, Platelets and Systemic Disorders
The Antiplatelet Effect of a New, Direct Acting, Reversible P2Y12 Inhibitor, Elinogrel (PRT060128) in Patients with High Platelet Reactivity During Clopidogrel Therapy (Presentation #PP-WE-801)
Presenter: Paul Gurbel Date: Wednesday, July 15, 12:30-2:15 p.m. Location: Poster Area, Patient Oriented Studies
|SOURCE Portola Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved